Toripalimab Injection Clinical Trials

6 actively recruiting trials across 1 location

▼ -1 trial since May 2026

Also known as: JS001, Toripalimab

Pipeline

Phase 2: 2Phase 3: 2Phase 1/2: 2

Top Sponsors

Wan He1
Suzhou Suncadia Biopharmaceuticals Co., Ltd.1
Shanghai Junshi Bioscience Co., Ltd.1
Risen (Suzhou) Pharma Tech Co., Ltd.1
Nanjing Leads Biolabs Co.,Ltd1

Indications

Cancer6
Breast Cancer2
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer1
Limited-stage Small Cell Lung Cancer (LS-SCLC)1
Urothelial Carcinoma1

Other5 trials

9MW2821 Combined With Toripalimab in Perioperative Patients With Urothelial Cancer

Phase 2

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Phase 1/2

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Phase 3

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

Phase 1/2

PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer

Phase 2

Goodyear, Arizona1 trial

Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

Banner MD Anderson Cancer Center

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.